93 related articles for article (PubMed ID: 31907132)
41. Assessment of urinary beta-core fragment of human chorionic gonadotropin as a new tumor marker of lung cancer.
Yoshimura M; Nishimura R; Murotani A; Miyamoto Y; Nakagawa T; Hasegawa K; Koizumi T; Shii K; Baba S; Tsubota N
Cancer; 1994 Jun; 73(11):2745-52. PubMed ID: 7514953
[TBL] [Abstract][Full Text] [Related]
42. Probable assignment of soluble isocitrate dehydrogenase (IDH1) to 2q33.3.
Narahara K; Kimura S; Kikkawa K; Takahashi Y; Wakita Y; Kasai R; Nagai S; Nishibayashi Y; Kimoto H
Hum Genet; 1985; 71(1):37-40. PubMed ID: 3861566
[TBL] [Abstract][Full Text] [Related]
43. [Clinical significance of recombinant virus-specific detection for viable circulating tumor cells in lung cancer patients].
Xiao Y; Liu S; Wang ZZ; Chen Y; Li J; Li F
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Feb; 42(2):101-105. PubMed ID: 30704181
[No Abstract] [Full Text] [Related]
44. IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.
Lee JH; Shin DH; Park WY; Shin N; Kim A; Lee HJ; Kim YK; Choi KU; Kim JY; Yang YI; Lee CH; Sol MY
World J Surg Oncol; 2017 Apr; 15(1):82. PubMed ID: 28403884
[TBL] [Abstract][Full Text] [Related]
45. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y
Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149
[TBL] [Abstract][Full Text] [Related]
47. Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis.
Yaman B; Nart D; Ekren PK; Çok G; Veral A
Turk Patoloji Derg; 2015; 31(3):163-74. PubMed ID: 26456962
[TBL] [Abstract][Full Text] [Related]
48. Serum lemur tyrosine kinase-3: a novel biomarker for screening primary non-small cell lung cancer and predicting cancer progression.
Zhang K; Chen L; Deng H; Zou Y; Liu J; Shi H; Xu B; Lu M; Li C; Jiang J; Wang Z
Int J Clin Exp Pathol; 2015; 8(1):629-35. PubMed ID: 25755755
[TBL] [Abstract][Full Text] [Related]
49. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
[TBL] [Abstract][Full Text] [Related]
50. Increased serum S-TRAIL level in newly diagnosed stage-IV lung adenocarcinoma but not squamous cell carcinoma is correlated with age and smoking.
Kargi A; Bisgin A; Yalcin AD; Kargi AB; Sahin E; Gumuslu S
Asian Pac J Cancer Prev; 2013; 14(8):4819-22. PubMed ID: 24083751
[TBL] [Abstract][Full Text] [Related]
51. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
52. Kinetic and physiological effects of alterations in homologous isocitrate-binding sites of yeast NAD(+)-specific isocitrate dehydrogenase.
Lin AP; McCammon MT; McAlister-Henn L
Biochemistry; 2001 Nov; 40(47):14291-301. PubMed ID: 11714283
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
54. Serum glutathione S-transferase-pi level as a tumor marker for non-small cell lung cancer. Potential predictive value in chemotherapeutic response.
Hida T; Kuwabara M; Ariyoshi Y; Takahashi T; Sugiura T; Hosoda K; Niitsu Y; Ueda R
Cancer; 1994 Mar; 73(5):1377-82. PubMed ID: 8111704
[TBL] [Abstract][Full Text] [Related]
55. Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.
Pujol JL; Cooper EH; Lehmann M; Purves DA; Dan-Aouta M; Midander J; Godard P; Michel FB
Br J Cancer; 1993 Jun; 67(6):1423-9. PubMed ID: 8390291
[TBL] [Abstract][Full Text] [Related]
56. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
57. Exploring the regulatory role of isocitrate dehydrogenase mutant protein on glioma stem cell proliferation.
Lu HC; Ma J; Zhuang Z; Qiu F; Cheng HL; Shi JX
Eur Rev Med Pharmacol Sci; 2016 Aug; 20(16):3378-84. PubMed ID: 27608896
[TBL] [Abstract][Full Text] [Related]
58. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
Pavićević R; Milicić J; Bubanović G; Supe S
Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
[TBL] [Abstract][Full Text] [Related]
59. Diagnosis value of serum soluble B7-H4 expression in non-small cell lung cancer.
Xu CH; Wang W; Wang YC; Lin Y; Zhang XW
Clin Respir J; 2018 Jan; 12(1):134-139. PubMed ID: 27216449
[TBL] [Abstract][Full Text] [Related]
60. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
